Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ProImmune Immune Formulation 200 is a patented dietary supplement designed to support immune health and overall wellness by promoting the body's natural production of glutathione, a key intracellular antioxidant. Developed by Dr. Albert B. Crum, this formulation utilizes L-cystine as an optimal carrier for L-cysteine into cells, facilitating efficient glutathione synthesis even under oxidative stress conditions. The product activates the Nrf2 gene pathway to enhance endogenous antioxidant enzyme production and supports detoxification processes at the cellular level. It is marketed for its potential benefits in immune defense, reduction of oxidative stress, tissue repair and regeneration, cognitive function optimization, cardiovascular health support through cholesterol processing assistance, skin health via collagen protection from oxidative damage, energy production enhancement at the cellular level, and liver function support through detoxification[1][2][5][8][9]. The supplement has been recognized for its stability under various environmental conditions and can be used as an ingredient in food products[9]. Peer-reviewed research has documented its antiviral properties and broader applications in human health[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ProImmune Immune Formulation 200.